A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

Acute myeloid leukemia (AML) patients with FLT3-ITD mutations have a high risk of relapse and death. FLT3 tyrosine kinase inhibitors improve overall survival, but their efficacy is limited and most patients who relapse will ultimately die of the disease. Even with potent FLT3 inhibition, the disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Lauren Y., Hizukuri, Yoshiyuki, Severson, Paul, Powell, Benjamin, Zhang, Chao, Ma, Yan, Narahara, Maiko, Sumi, Hiroyuki, Hernandez, Daniela, Rajkhowa, Trivikram, Bollag, Gideon, Levis, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017818/
https://www.ncbi.nlm.nih.gov/pubmed/33504139
http://dx.doi.org/10.3324/haematol.2020.247346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017818/
https://www.ncbi.nlm.nih.gov/pubmed/33504139
http://dx.doi.org/10.3324/haematol.2020.247346

Ejemplares similares